Molecular pathology is an essential part of pathology complementing conventional morphological tools to obtain a correct integrated diagnosis with appropriate assessment of prognosis and prediction of response to therapy, particularly in cancer. There is a concern about the situation of molecular pathology in some areas of Europe, namely, regarding the central role of pathologists in assessing somatic genomic alterations in cancer. In some countries, there are attempts that other laboratory medicine specialists perform the molecular analysis of somatic alterations in cancer, particularly now when next generation sequencing (NGS) is incorporated into clinical practice. In this scenario, pathologists may play just the role of "tissue providers," and other specialists may take the lead in molecular analysis. Geneticists and laboratory medicine specialists have all background and skills to perform genetic analysis of germline alterations in hereditary disorders, including familial forms of cancers. However, interpretation of somatic alterations of cancer belongs to the specific scientific domain of pathology. Pathologists are necessary to guarantee the quality of the results, for several reasons: (1) The identified molecular alterations should be interpreted in the appropriate morphologic context, since most of them are context-specific; (2) pre-analytical issues must be taken into consideration; (3) it is crucial to check the proportion of tumor cells in the sample subjected to analysis and presence of inflammatory infiltrate and necrosis should be monitored; and 4) the role of pathologists is crucial to select the most appropriate methods and to control the turnaround time in which the molecular results are delivered in the context of an integrated diagnosis. Obviously, there is the possibility of having core facilities for NGS in a hospital to perform the sequence analysis that are open to other specialties (microbiologists, geneticists), but also in this scenario, pathologists should have the lead in assessing somatic alterations of cancer. In this article, we emphasize the importance of interpreting somatic molecular alterations of the tumors in the context of morphology. In this Position Paper of the European Society of Pathology, we strongly support a central role of pathology departments in the process of analysis and interpretation of somatic molecular alterations in cancer.

Department of Medical Sciences University of Trieste Trieste Italy

Department of Pathology Medical Faculty of the University of Porto Centro Hospitalar Universitário São João and Ipatimup i3S Porto Portugal

Diagnostic and Research Institute of Pathology D and R Center of Molecular BioMedicine Medical University of Graz Graz Austria

Hospital Universitari Arnau de Vilanova Universitat de Lleida IRBLleida CIBERONC Hospital U de Bellvitge IDIBELL University of Barcelona Av Rovira Roure 80 25198 Lleida Spain

Institute for Pathology and Molecular Pathology University Hospital Zurich Zurich Switzerland

The Fingerland Department of Pathology Charles University Medical Faculty and University Hospital Hradec Kralove Czech Republic

Virchows Arch. 2021 Feb;478(2):379-380. doi: 10.1007/s00428-020-02898-2. PubMed

See more in PubMed

Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546–1558. doi: 10.1126/science.1235122. PubMed DOI PMC

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. doi: 10.1016/j.cell.2011.02.013. PubMed DOI

Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. 2015;6:32602–32609. PubMed PMC

Pena GP, de Andrade-Filho JS. How does a pathologist make a diagnosis? Arch Pathol Lab Med. 2009;133:124–132. PubMed

Srigley JR. The pathologist as diagnostic oncologist. Pathology. 2009;41:513–514. doi: 10.1080/00313020903121887. PubMed DOI

Walk EE. The role of pathologists in the era of personalized medicine. Arch Pathol Lab Med. 2009;133:605–610. PubMed

Salto-Tellez M, James JA, Hamilton PW. Molecular pathology - the value of an integrative approach. Mol Oncol. 2014;8:1163–1168. doi: 10.1016/j.molonc.2014.07.021. PubMed DOI PMC

Parums DV. The role of pathologist in the era of personalized medicine. SM J Clin Pathol. 2016;1:1003.

Rodriguez-Canales J, Eberle FC, Jaffe ES, Emmert-Buck MR. Why is it crucial to reintegrate pathology into cancer research? Bioessays. 2011;33:490–498. doi: 10.1002/bies.201100017. PubMed DOI PMC

Ince TA, Ward JM, Valli VE, Sgroi D, Nikitin AY, Loda M, Griffey SM, Crum CP, Crawford JM, Bronson RT, Cardiff RD. Do-it-yourself (DIY) pathology. Nat Biotechnol. 2008;26:978–979. doi: 10.1038/nbt0908-978. PubMed DOI

Horlings HM, Shah SP, Huntsman DG. Using somatic mutations to guide treatment decisions: context matters. JAMA Oncol. 2015;1:275–276. doi: 10.1001/jamaoncol.2015.35. PubMed DOI

Schneider G, Schmidt-Supprian M, Rad R, Saur D. Tissue-specific tumorigenesis: context matters. Nat Rev Cancer. 2017;17:239–253. doi: 10.1038/nrc.2017.5. PubMed DOI PMC

Sieber OM, Tomlinson SR, Tomlinson IP. Tissue, cell and stage specificity of (epi)mutations in cancers. Nat Rev Cancer. 2005;5:649–655. doi: 10.1038/nrc1674. PubMed DOI

Schaefer MH, Serrano L. Cell type-specific properties and environment shape tissue specificity of cancer genes. Sci Rep. 2016;6:20707. doi: 10.1038/srep20707. PubMed DOI PMC

Chandarlapaty S. Negative feedback and adaptive resistance to the targeted therapy of cancer. Cancer Discov. 2012;2:311–319. doi: 10.1158/2159-8290.CD-12-0018. PubMed DOI PMC

Dubbink HJ, Deans ZC, Tops BB, van Kemenade FJ, Koljenović S, van Krieken HJ, Blokx WA, Dinjens WN, Groenen PJ. Next generation diagnostic molecular pathology: critical appraisal of quality assurance in Europe. Mol Oncol. 2014;8:830–839. doi: 10.1016/j.molonc.2014.03.004. PubMed DOI PMC

Bosman FT. Tumor heterogeneity: will it change what pathologists do. Pathobiology. 2018;85:18–22. doi: 10.1159/000469664. PubMed DOI

Venkatesan S, Swanton C. Tumor evolutionary principles: how Intratumor heterogeneity influences Cancer treatment and outcome. Am Soc Clin Oncol Educ Book. 2016;35:e141–e149. doi: 10.14694/EDBK_158930. PubMed DOI

Griffin J, Treanor D. Digital pathology in clinical use: where are we now and what is holding us back? Histopathology. 2017;70:134–145. doi: 10.1111/his.12993. PubMed DOI

Niazi MKK, Parwani AV, Gurcan MN. Digital pathology and artificial intelligence. Lancet Oncol. 2019;20:e253–e261. doi: 10.1016/S1470-2045(19)30154-8. PubMed DOI PMC

Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E. Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch. 2016;469:489–503. doi: 10.1007/s00428-016-2000-3. PubMed DOI PMC

Garber K. Tissue-agnostic cancer drug pipeline grows, despite doubts. Nat Rev Drug Discov. 2018;17:227–229. doi: 10.1038/nrd.2018.6. PubMed DOI

Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731–747. doi: 10.1038/s41571-018-0113-0. PubMed DOI PMC

Penault-Llorca F, Rudzinski ER, Sepulveda AR. Testing algorithm for identification of patients with TRK fusion cancer. J Clin Pathol. 2019;72:460–467. doi: 10.1136/jclinpath-2018-205679. PubMed DOI PMC

Ryska A, Berzinec P, Brcic L, Cufer T, Dziadziuszko R, Gottfried M, Kovalszky I, Olszewski W, Oz B, Plank L, Timar J. NSCLC molecular testing in Central and Eastern European countries. BMC Cancer. 2018;18:269. doi: 10.1186/s12885-018-4023-4. PubMed DOI PMC

Hicks DG, Boyce BF. The challenge and importance of standardizing pre-analytical variables in surgical pathology specimens for clinical care and translational research. Biotech Histochem. 2012;87:14–17. doi: 10.3109/10520295.2011.591832. PubMed DOI

Compton CC, Robb JA, Anderson MW, Berry AB, Birdsong GG, Bloom KJ, Branton PA, Crothers JW, Cushman-Vokoun AM, Hicks DG, Khoury JD, Laser J, Marshall CB, Misialek MJ, Natale KE, Nowak JA, Olson D, Pfeifer JD, Schade A, Vance GH, Walk EE, Yohe SL. Preanalytics and precision pathology: pathology practices to ensure molecular integrity of cancer patient biospecimens for precision medicine. Arch Pathol Lab Med. 2019;143:1346–1363. doi: 10.5858/arpa.2019-0009-SA. PubMed DOI

de Jong D, Verbeke S, Meijer D, Hogendoorn PC, Bovee JV, Szuhai K. Opening the archives for state of the art tumour genetic research: sample processing for array-CGH using decalcified, formalin-fixed, paraffin-embedded tissue-derived DNA samples. BMC Res Notes. 2011;4:1. doi: 10.1186/1756-0500-4-1. PubMed DOI PMC

Groenen PJ, Blokx WA, Diepenbroek C, Burgers L, Visinoni F, Wesseling P, van Krieken JH. Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase. Histopathology. 2011;59:1–7. doi: 10.1111/j.1365-2559.2010.03711.x. PubMed DOI

Dotti I, Bonin S, Basili G, Nardon E, Balani A, Siracusano S, Zanconati F, Palmisano S, De Manzini N, Stanta G. Effects of formalin, methacarn, and fineFIX fixatives on RNA preservation. Diagn Mol Pathol. 2010;19:112–122. doi: 10.1097/PDM.0b013e3181b520f8. PubMed DOI

Heinmöller E, Renke B, Beyser K, Dietmaier W, Langner C, Rüschoff J. Piffalls in diagnostic molecular pathology--significance of sampling error. Virchows Arch. 2001;439:504–511. doi: 10.1007/s004280100450. PubMed DOI

Digital transformation of pathology - the European Society of Pathology expert opinion paper

Expanding horizons in a new era for pathology: perspectives from the ASCO meeting

Expert opinion on NSCLC small specimen biomarker testing - Part 1: Tissue collection and management